Alopecia News

Coacillium solution 22.25% improved moderate to severe alopecia in children and adolescents while retaining results post-treatment, according to a study presented at the European Academy of Dermatology and Venereology 2023 Congress.

Each year, WHO marks World Mental Health Day on Oct. 10 in an effort to raise awareness of mental health issues around the world and mobilize efforts to support mental health.

Healio Dermatology has published a list of the most recent alopecia news consisting of treatments and practices of which dermatologists should be aware.

In a literature review evaluating the findings of two identical phase 3 trials of baricitinib, the oral Janus kinase 1/2 inhibitor was found to be efficacious, safe and “relatively tolerable” in the treatment of severe alopecia areata.

Platelet-rich plasma therapy may be more effective than minoxidil in treating androgenetic alopecia, according to a study.

Women who wear hijab are among the highest risk for developing traction alopecia, yet they are likely underrepresented in alopecia studies, according to a letter in Journal of the American Academy of Dermatology.

As we close out National Hair Loss Awareness Month, marked each year in August, Healio Dermatology has compiled the most read alopecia stories of 2023.

Pooled analysis of two clinical trials found patients with alopecia who did not respond to 2 mg of baricitinib had a significant improvement with a 4 mg dose.

Cryotherapy may lower disease relapse in patients with alopecia areata compared with intralesional corticosteroid injections or topical steroids, according to a study.

Efficacy and safety outcomes in adolescents treated with ritlecitinib for severe alopecia areata were consistent with adults in the same indication, according to a subgroup analysis of a phase 2b/3 trial.